The in vitro effects of remifentanil and fentanyl on isolated human right atria and saphenous veins.
OBJECTIVE
To determine the myocardial and vascular effects of remifentanil and fentanyl in human atria and saphenous veins.


METHODS
In vitro, prospective with repeated measures.


METHODS
University research laboratory.


METHODS
The direct effects of remifentanil and fentanyl on the electrical stimulation-induced contraction of nonfailing human atrium and saphenous veins contracted with 5-hydroxytryptamine were studied.


RESULTS
In human atrial trabeculae, cumulative (10(-9)-10(-5) mol/L) added remifentanil had no effect on contractile force, compared with untreated muscles (p > 0.05). The force of contraction was significantly less than control values with concentrations of fentanyl ranging from 10(-8) to 10(-5) mol/L (p < 0.05). At the highest concentration (10(-5) mol/L), the inhibition by fentanyl of the electrical stimulation-induced contraction was 40.6% +/- 6.32%. In human saphenous vein strips preconstricted with 5-hydroxytryptamine, remifentanil (10(-8)-10(-5) mol/L) and fentanyl (10(-8)-10(-5) mol/L) produced "concentration-dependent" relaxation when compared with the control contraction value (p < 0.05). The IC(50) was similar with remifentanil and fentanyl and the E(max) of fentanyl was significantly higher than remifentanil (p < 0.05). The venodilatory effects of remifentanil and fentanyl were similar on veins with or without endothelium (p > 0.05).


CONCLUSIONS
Remifentanil has no direct effect on the contraction of myocardium. Fentanyl inhibits the electrical stimulation-induced contraction in human right atrial muscles in vitro. Remifentanil and fentanyl produce "concentration-dependent" relaxation in human saphenous vein strips independent from the endothelium.
Duman
Ates
A
Department of Anesthesiology and Intensive Care, University of Selcuk, Konya, Turkey. atesduman@hotmail.com
Saide Sahin
Ayse
A
Esra Atalik
Kismet
K
öZtin ögün
Cemile
C
Basri Ulusoy
Hasan
H
Durgut
Kadir
K
öKesli
Selmin
S
D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000627:therapeutic use*; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006325:Heart Atria / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D000077208:Remifentanil; D015203:Reproducibility of Results; D012501:Saphenous Vein / Q000187:drug effects*; D012701:Serotonin / Q000627:therapeutic use; D013318:Stroke Volume / Q000502:physiology; D013997:Time Factors; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects
D000701:Analgesics, Opioid; D016166:Free Radical Scavengers; D010880:Piperidines; D012701:Serotonin; D000077208:Remifentanil; D005283:Fentanyl